Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Sarina Isenberg, PhD Candidate, of the Johns Hopkins Bloomberg School of Public Health, discusses the cost savings of a comprehensive hospital-based palliative care program. (Abstract 2)
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
Craig Earle, MD, of Canada’s Institute for Clinical Evaluative Sciences, summarizes abstracts discussed in a ticketed session that he co-chaired on this key topic. (Abstracts 173, 174, 175)
